• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transcatheter aortic valve replacement for patients with severe bicuspid aortic stenosis
ConclusionsThis initial experience suggests TAVR can be safely performed in patients with BAV achieving similar short-term procedural and clinical outcomes when compared with patients with TAV.Condensed AbstractThe outcomes of 50 patients (8.8%) with bicuspid aortic stenosis (BAV) undergoing TAVR were compared with those of 517 patients (91.2%) with trileaflet aortic valve (TAV) stenosis. Patients with BAV were younger, had higher prevalence of COPD, lower prevalence of CAD, higher BMI and lower STS score. Major complications were similar between the groups, including stroke (2.0% vs. 1.5, P = .567), 30-day all-c...
Source: American Heart Journal - February 9, 2020 Category: Cardiology Source Type: research

Rationale and design of the randomized, controlled early valve replacement guided by biomarkers of left ventricular decompensation in asymptomatic patients with severe aortic stenosis (EVOLVED) trial
ConclusionThe EVOLVED trial is the first multicenter randomized controlled trial to compare early aortic valve replacement to routine care in asymptomatic patients with severe aortic stenosis and mid-wall LGE.
Source: American Heart Journal - March 15, 2019 Category: Cardiology Source Type: research

EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 30, 2018 Category: Cardiology Source Type: research

Oral anti-Xa anticoagulation after Trans-Aortic Valve Implantation for Aortic Stenosis: The randomized ATLANTIS trial
Conclusions ATLANTIS tests the superiority of an apixaban-based strategy versus the recommended standard of care strategy to reduce the risk of post-TAVR thromboembolic and bleeding complications in an all comer population.
Source: American Heart Journal - March 10, 2018 Category: Cardiology Source Type: research

Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial
Publication date: Available online 26 August 2016 Source:American Heart Journal Author(s): Ernest Spitzer, Nicolas M. Van Mieghem, Philippe Pibarot, Rebecca T. Hahn, Susheel Kodali, Mathew S. Maurer, Tamim M. Nazif, Josep Rodés-Cabau, Jean-Michel Paradis, Arie-Pieter Kappetein, Ori Ben-Yehuda, Gerrit-Anne van Es, Faouzi Kallel, William N. Anderson, Jan Tijssen, Martin B. Leon Background Co-existence of moderate aortic stenosis (AS) in patients with heart failure with reduced ejection fraction (HFrEF) is not uncommon. Moderate AS increases afterload, while pharmacological reduction of afterload is a pillar of contemporary...
Source: American Heart Journal - August 26, 2016 Category: Cardiology Source Type: research

Transcatheter aortic valve replacement: Historical perspectives, current evidence, and future directions
Severe aortic stenosis (AS) results in considerable morbidity and mortality without aortic valve replacement and is expected to increase in prevalence with the aging population. Because AS primarily affects the elderly, many patients with comorbidities are poor candidates for surgical aortic valve replacement (SAVR) and may not be referred. Transcatheter aortic valve replacement (TAVR) has emerged as transformative technology for the management of AS over the past decade. Randomized trials have established the safety and efficacy of TAVR with improved mortality and quality of life compared with medical therapy in inoperabl...
Source: American Heart Journal - July 30, 2014 Category: Cardiology Authors: Aaron Horne, Elizabeth A. Reineck, Rani K. Hasan, Jon R. Resar, Matthews Chacko Tags: Curriculum in Cardiology Source Type: research

Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: Acute and long-term outcomes
Background: The use of balloon aortic valvuloplasty (BAV) has resurged since the development of transcatheter aortic valve replacement (TAVR). The aim of our study was to determine the procedural and long-term outcomes of patients treated by BAV in the early TAVR era.Methods: From 2005 to 2008, 323 consecutive patients presenting with severe aortic stenosis were treated by BAV in our institution.Results: Mean age and logistic EuroSCORE were 80.5 ± 9.9 years and 28.7% ± 12.5%, respectively. The effective orifice area increased from 0.68 ± 0.25 to 1.12 ± 0.39 cm2 (P
Source: American Heart Journal - November 6, 2013 Category: Cardiology Authors: Hélène Eltchaninoff, Eric Durand, Bogdan Borz, Akira Furuta, Karim Bejar, Alexandre Canville, Ali Farhat, Chiara Fraccaro, Matthieu Godin, Christophe Tron, Rahul Sakhuja, Alain Cribier Tags: Valvular and Congenital Heart Disease Source Type: research